Response to Reviewer 2 Comments

Comments and Suggestions for Authors

Yong Hoon Kim and colleagues investigated the 2-year efficacy of statin treatment according to baseline renal function in patients with acute myocardial infarction not requiring dialysis undergoing newer-generation DES implantation. They classified a large (18875) group of AMI patients in statin users and statin non users and showed that MACE, all-cause death, and cardiac death are significantly higher in statin non users. However, statin beneficial effect was diminished in accordance with the deterioration of baseline renal function in patients with AMI who underwent successful PCI, improving the knowledge about statin effect on AMI patients.

The study was well designed and clearly presented. It has several limitations that however are already underlined by the same authors in the manuscript.

I think inserting table s2 and s4 in the main manuscript would be useful for the readers

Point 1: I think inserting table s2 and s4 in the main manuscript would be useful for the readers

Response 1: We sincerely thank you for reviewer's valuable comments and recommendations. According to reviewer's recommendations, we inserted Table S2, S3, and S4 as Table 2, 3, and 4. Therefore, original Table 2, 3, and 4 are renamed as Table 5, 6, and 7. Moreover, the original Table S5 and S6 are renamed as Table S2 and S3.

Before,

Table legends

Table 1. Baseline characteristics of statin users.

Table 2. Hazard ratios for 2-year major clinical outcomes in statin users.

Table 3. Clinical outcomes between statin users and nonusers at 2 years.

Table 4. Independent predictors for MACE and all-cause death in statin users

After,

Table legends

Table 1. Baseline characteristics of statin users.

Table 2. Baseline characteristics in statin nonusers.

Table 3. Baseline characteristics between statin users and nonusers 1.

Table 4. Baseline characteristics between statin users and nonusers 2.

Table 5. Hazard ratios for the 2-year major clinical outcomes in statin users.

Table 6. Clinical outcomes between statin users and nonusers at 2 years.

Table 7. Independent predictors for MACE and all-cause death in statin users.

Before,

Supplementary Materials: Table S1: Univariate analysis for MACE. Table S2: Baseline characteristics in statin nonusers. Table S3: Baseline characteristics between statin users and nonusers 1. Table S4: Baseline characteristics between statin users and nonusers 2. Table S5: Hazard ratios for the 2-year major clinical outcomes in statin nonusers. Table S6: Independent predictors for MACE and all-cause death in statin nonusers.

After,

Supplementary Materials: Table S1: Univariate analysis for MACE. Table S2: Hazard ratios for the 2-year major clinical outcomes in statin nonusers. Table S3: Independent predictors for MACE and all-cause death in statin nonusers.

We thank you very much for Reviewer's efforts in evaluating our submission. We also thank the Reviewer for the helpful and valuable comments, which was very helpful to us to improve our manuscript.

We hope respected Reviewer 2 is healthy and happy

Yong Hoon Kim, M.D., Ph.D.